Aesthetics
A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines
Dermatologic Surgery
- Author: Green, Jeremy B. MD et al.
Clinical Highlights
Aesthetics
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
Dermatologic Surgery
- Author: Fabi, Sabrina G. MD et al.
Aesthetics
Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds
Dermatologic Surgery
- Author: Gary Monheit, M.D.
Aesthetics
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
Journal of the American Academy of Dermatology
- Author: Vince Bertucci, M.D. et al
Aesthetics
Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles
Dermatologic Surgery
- Author: Berthold Rzany, M.D. et al
Aesthetics
DaxibotulinumtoxinA in the treatment of glabellar lines. Results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
Plastic and Reconstructive Surgery
- Author: Jean Carruthers M.D. et al
Disclaimers
DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. Anticipated approval in 2020
* DaxibotulinumtoxinA for Injection was formerly known as RT002.